Congress caps inhaler costs at $15/month for asthma and COPD patients

What it does

This bill caps patient cost-sharing for prescription inhalers and related equipment at $15 per 30-day supply across private insurance, Medicare Part B, Medicare Part D, and creates a federal payment program for uninsured individuals. It applies to maintenance, reliever, and rescue inhalers used to treat asthma and COPD, and allows high-deductible and catastrophic health plans to waive deductibles for these drugs without losing their tax-advantaged status.

Why we flagged it

The bill's operative mechanism is a straightforward price ceiling ($15/month) on inhaler cost-sharing across all insurance types and a federal subsidy for the uninsured. It is not a deregulation, subsidy to manufacturers, or liability shield—it is a consumer price protection.

What the text implies

• The $15 cap applies to cost-sharing only, not to the underlying drug price; manufacturers retain pricing power, and insurers may respond by raising premiums or narrowing formularies to offset the capped copay.
• The federal payment program for uninsured individuals (Section 399V–8) is discretionary and subject to appropriations; without dedicated funding, it may be underfunded or unused, leaving uninsured patients without the promised backstop.
• The bill does not address prior authorization, step therapy, or formulary restrictions; insurers may still delay or deny access to inhalers even if the copay is capped, undermining the bill's intent.
• High-deductible and catastrophic plan safe harbors allow plans to waive deductibles for inhalers without losing tax-advantaged status, but may incentivize plans to shift costs to other services or raise premiums to compensate.
• The definition of 'specified inhaler product' includes equipment (masks, tubing, spacers, nebulizers) but does not clarify whether the $15 cap applies per item or per 30-day supply of the entire bundle, creating potential ambiguity in implementation.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people with asthma and COPD gain direct, measurable relief: a hard cap on out-of-pocket costs ($15/month) across all major insurance pathways and a federal backstop for the uninsured. The bill removes cost barriers to essential maintenance medications, which improves health outcomes and reduces emergency-room utilization. No offsetting cost to the public is visible in the text.

Who stands to gain

• Patients with asthma and COPD (primary beneficiaries—direct cost reduction)
• Pharmaceutical manufacturers of inhaler products (potential volume increase due to reduced cost barr
• Healthcare providers administering inhalers to uninsured patients (federal reimbursement under Secti

Named in the bill

Bristol Myers Squibb (BMY), Grifols (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), Private health insurers, Medicare Part B and Part D

Where it stands

2 cosponsors: 2 Democrats.

• Sep 10, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 10, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $120,000 in lobbying spend. A filing names 54 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Angela Alsobrooks, the sponsor, reported $493,679 in PAC receipts in the 2026 cycle.

• American Lung Association — $120,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.